NasdaqGM - Delayed Quote USD

Sagimet Biosciences Inc. (SGMT)

8.27
-0.34
(-3.95%)
At close: June 13 at 4:00:00 PM EDT
8.34
+0.07
+(0.85%)
After hours: June 13 at 7:56:25 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. David A. Happel CEO, President & Director 906.16k -- 1962
Mr. Thierry Chauche CFO & Principal Accounting Officer 598.04k -- 1976
Dr. Eduardo Bruno Martins DPhil, M.D., Ph.D. Chief Medical Officer 669.06k -- 1963
Mr. Urs Greber Ph.D. Co-Founder -- -- --
Dr. Lucas Pelkmans Ph.D. Co-Founder -- -- --
Ms. Elizabeth Rozek Esq., J.D. General Counsel & Chief Compliance Officer -- -- 1972
Dr. Marie O'Farrell Ph.D. Senior Vice President of Research & Development -- -- --
Mr. Robert D'Urso Senior Vice President of New Products -- -- --

Sagimet Biosciences Inc.

155 Bovet Road
Suite 303
San Mateo, CA 94402
United States
650 561 8600 https://www.sagimet.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
14

Description

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs, such as various solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Corporate Governance

Sagimet Biosciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 8, 2025 at 10:00 AM UTC

Sagimet Biosciences Inc. Earnings Date

Recent Events

June 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 4, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 8, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2025 at 12:00 AM UTC

ARS: Annual Report to Shareholders

March 12, 2025 at 12:00 AM UTC

S-8: Offering Registrations

March 11, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 2, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 22, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

Related Tickers